License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for use with two Pfizer transgenes in neurologic and cardiovascular disease TRACER platform identifies

Reader Interactions

Leave A Reply